Loading
Runs the NCT/DKTK MASTER programme that sequences whole genomes of rare and young-adult cancers to guide therapy.
Stefan Fröhling is Managing Director of NCT Heidelberg and Head of Translational Medical Oncology at the German Cancer Research Center (DKFZ). His specialisms are precision oncology, sarcoma and genomics-guided trials, using whole-exome and whole-genome sequencing and comprehensive genomic profiling. He runs the NCT/DKTK MASTER programme, which sequences the whole genomes of rare and young-adult cancers to guide therapy. His Cancer Discovery paper on MASTER described comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. His focus is on sarcomas and rare cancers and on turning genomic findings into molecularly guided treatment. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers (MASTER) | Cancer Discovery | 2021 |
Shares Deutsches Netzwerk für Personalisierte Medizin, Comprehensive genomic profiling.
Shares German Cancer Consortium (DKTK), Deutsches Netzwerk für Personalisierte Medizin, German Cancer Research Center (DKFZ).
Shares Heidelberg University Hospital / NCT / DKFZ, German Cancer Research Center (DKFZ).
Shares Heidelberg University Hospital / NCT / DKFZ, German Cancer Research Center (DKFZ).
Shares German Cancer Consortium (DKTK), Deutsches Netzwerk für Personalisierte Medizin, Heidelberg University Hospital / NCT / DKFZ, German Cancer Research Center (DKFZ).
Shares German Cancer Consortium (DKTK), Deutsches Netzwerk für Personalisierte Medizin, German Cancer Research Center (DKFZ).
Shares Heidelberg University Hospital / NCT / DKFZ, German Cancer Research Center (DKFZ), Whole-exome & whole-genome sequencing.
Shares Whole-exome & whole-genome sequencing, Comprehensive genomic profiling.